Comparative Pharmacology
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus CEFOTAN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFEPIME HYDROCHLORIDE versus CEFOTAN IN PLASTIC CONTAINER.
CEFEPIME HYDROCHLORIDE vs CEFOTAN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase and carboxypeptidase activity, leading to cell lysis.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and cross-linking of peptidoglycan. It has broad-spectrum activity against gram-negative and gram-positive bacteria, including anaerobes, and is resistant to beta-lactamases.
1-2 g IV every 8-12 hours; for uncomplicated urinary tract infections, 500 mg IV every 12 hours.
1 to 2 g intravenously or intramuscularly every 12 hours for 5 to 10 days. Maximum dose 6 g daily.
None Documented
None Documented
2-2.3 hours in healthy adults (prolonged to 13-15 hours in severe renal impairment; requires dosage adjustment).
2.8-3.2 hours in normal renal function; prolonged to 12-30 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (≈85% unchanged via glomerular filtration and tubular secretion); biliary/fecal <1%.
Primarily renal (76-85% unchanged in urine via glomerular filtration and tubular secretion); biliary excretion accounts for <10%, with small amounts in feces.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic